Eric Lefkofsky Could Help Revolutionize Cancer Research

Eric Lefkofsky is a US businessman who is most well-known for his company Groupon. His latest professional venture is Tempus which could revolutionize how we approach cancer treatments and research in the future. Tempus has a goal to create a genomic database of cancer which would allow physicians to specifically target the therapeutic efforts to combat cancer by comparing cancer patient’s DNA from around the world. After discovering that the technology to create such a database was becoming more accessible and that the data was already there, it seemed like a no-brainer to help establish a database that would help physicians analyze this data.Tempus has teamed up with some of the most reputable hospitals to collect data and has already implemented a 20,000-square ft. lab where gene-sequencing will be performed. Once the database is built, Tempus will provide physicians with software to help them analyze data with ease. Tempus isn’t just a company, it could pave the way to miraculous scientific discoveries surrounding one of the most serious conditions plaguing the world today.

About the Entrepreneur and Businessman Eric Lefkofsky

Aside from Tempus and Groupon, Eric Lefkofsky is a founding partner of Lightbank and a co-founder of Uptake Technologies. Prior to his successful career as a serial entrepreneur and businessman in the Chicago area, Eric Lefkofsky attended the University of Michigan and the University of Michigan Law School.

Tempus isn’t the first technological or medical based venture that Eric has teamed up with or facilitated. Eric and his wife Liz established the Lefkofsky Family Foundation in 2006 to help fast track research, programs, and initiatives aimed at improving the quality of life for people at home and around the world. The Lefkofsky’s have also made significant donations to cancer centers, as well as gastric and breast cancer research. If Tempus is as successful as his previous ventures, you can be sure that it is sure to make waves throughout the medical, scientific, and technological communities.

Leave a Reply

Your email address will not be published. Required fields are marked *